Therapeutic Silencing of miR-214 Inhibits Tumor Progression in Multiple Mouse Models

Daniela Dettori, Francesca Orso, Elisa Penna, Désirée Baruffaldi, Serena Brundu, Federica Maione, Emilia Turco, Enrico Giraudo, Daniela Taverna

Research output: Contribution to journalArticle

Abstract

We previously demonstrated that miR-214 is upregulated in malignant melanomas and triple-negative breast tumors and promotes metastatic dissemination by affecting a complex pathway including the anti-metastatic miR-148b. Importantly, tumor dissemination could be reduced by blocking miR-214 function or increasing miR-148b expression or by simultaneous interventions. Based on this evidence, with the intent to explore the role of miR-214 as a target for therapy, we evaluated the capability of new chemically modified anti-miR-214, R97/R98, to inhibit miR-214 coordinated metastatic traits. Relevantly, when melanoma or breast cancer cells were transfected with R97/R98, anti-miR-214 reduced miR-214 expression and impaired transendothelial migration were observed. Noteworthy, when the same cells were injected in the tail vein of mice, cell extravasation and metastatic nodule formation in lungs were strongly reduced. Thus, suggesting that R97/R98 anti-miR-214 oligonucleotides were able to inhibit tumor cell escaping through the endothelium. More importantly, when R97/R98 anti-miR-214 compounds were systemically delivered to mice carrying melanomas or breast or neuroendocrine pancreatic cancers, a reduced number of circulating tumor cells and lung or lymph node metastasis formation were detected. Similar results were also obtained when AAV8-miR-214 sponges were used in neuroendocrine pancreatic tumors. Based on this evidence, we propose miR-214 as a promising target for anti-metastatic therapies.

Original languageEnglish
Pages (from-to)2008-2018
Number of pages11
JournalMolecular Therapy
Volume26
Issue number8
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint

R 97
Melanoma
Neoplasms
Breast Neoplasms
Transendothelial and Transepithelial Migration
Circulating Neoplastic Cells
Lung
Neuroendocrine Tumors
Porifera
Therapeutics
Pancreatic Neoplasms
Oligonucleotides
Endothelium
Tail
Veins
Breast
Lymph Nodes
Neoplasm Metastasis

Keywords

  • anti-mir-214
  • metastasis
  • tumor progression

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Dettori, D., Orso, F., Penna, E., Baruffaldi, D., Brundu, S., Maione, F., ... Taverna, D. (2018). Therapeutic Silencing of miR-214 Inhibits Tumor Progression in Multiple Mouse Models. Molecular Therapy, 26(8), 2008-2018. https://doi.org/10.1016/j.ymthe.2018.05.020

Therapeutic Silencing of miR-214 Inhibits Tumor Progression in Multiple Mouse Models. / Dettori, Daniela; Orso, Francesca; Penna, Elisa; Baruffaldi, Désirée; Brundu, Serena; Maione, Federica; Turco, Emilia; Giraudo, Enrico; Taverna, Daniela.

In: Molecular Therapy, Vol. 26, No. 8, 01.08.2018, p. 2008-2018.

Research output: Contribution to journalArticle

Dettori, D, Orso, F, Penna, E, Baruffaldi, D, Brundu, S, Maione, F, Turco, E, Giraudo, E & Taverna, D 2018, 'Therapeutic Silencing of miR-214 Inhibits Tumor Progression in Multiple Mouse Models', Molecular Therapy, vol. 26, no. 8, pp. 2008-2018. https://doi.org/10.1016/j.ymthe.2018.05.020
Dettori, Daniela ; Orso, Francesca ; Penna, Elisa ; Baruffaldi, Désirée ; Brundu, Serena ; Maione, Federica ; Turco, Emilia ; Giraudo, Enrico ; Taverna, Daniela. / Therapeutic Silencing of miR-214 Inhibits Tumor Progression in Multiple Mouse Models. In: Molecular Therapy. 2018 ; Vol. 26, No. 8. pp. 2008-2018.
@article{82878e2e4b534e778b1d4e694e334e18,
title = "Therapeutic Silencing of miR-214 Inhibits Tumor Progression in Multiple Mouse Models",
abstract = "We previously demonstrated that miR-214 is upregulated in malignant melanomas and triple-negative breast tumors and promotes metastatic dissemination by affecting a complex pathway including the anti-metastatic miR-148b. Importantly, tumor dissemination could be reduced by blocking miR-214 function or increasing miR-148b expression or by simultaneous interventions. Based on this evidence, with the intent to explore the role of miR-214 as a target for therapy, we evaluated the capability of new chemically modified anti-miR-214, R97/R98, to inhibit miR-214 coordinated metastatic traits. Relevantly, when melanoma or breast cancer cells were transfected with R97/R98, anti-miR-214 reduced miR-214 expression and impaired transendothelial migration were observed. Noteworthy, when the same cells were injected in the tail vein of mice, cell extravasation and metastatic nodule formation in lungs were strongly reduced. Thus, suggesting that R97/R98 anti-miR-214 oligonucleotides were able to inhibit tumor cell escaping through the endothelium. More importantly, when R97/R98 anti-miR-214 compounds were systemically delivered to mice carrying melanomas or breast or neuroendocrine pancreatic cancers, a reduced number of circulating tumor cells and lung or lymph node metastasis formation were detected. Similar results were also obtained when AAV8-miR-214 sponges were used in neuroendocrine pancreatic tumors. Based on this evidence, we propose miR-214 as a promising target for anti-metastatic therapies.",
keywords = "anti-mir-214, metastasis, tumor progression",
author = "Daniela Dettori and Francesca Orso and Elisa Penna and D{\'e}sir{\'e}e Baruffaldi and Serena Brundu and Federica Maione and Emilia Turco and Enrico Giraudo and Daniela Taverna",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.ymthe.2018.05.020",
language = "English",
volume = "26",
pages = "2008--2018",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Therapeutic Silencing of miR-214 Inhibits Tumor Progression in Multiple Mouse Models

AU - Dettori, Daniela

AU - Orso, Francesca

AU - Penna, Elisa

AU - Baruffaldi, Désirée

AU - Brundu, Serena

AU - Maione, Federica

AU - Turco, Emilia

AU - Giraudo, Enrico

AU - Taverna, Daniela

PY - 2018/8/1

Y1 - 2018/8/1

N2 - We previously demonstrated that miR-214 is upregulated in malignant melanomas and triple-negative breast tumors and promotes metastatic dissemination by affecting a complex pathway including the anti-metastatic miR-148b. Importantly, tumor dissemination could be reduced by blocking miR-214 function or increasing miR-148b expression or by simultaneous interventions. Based on this evidence, with the intent to explore the role of miR-214 as a target for therapy, we evaluated the capability of new chemically modified anti-miR-214, R97/R98, to inhibit miR-214 coordinated metastatic traits. Relevantly, when melanoma or breast cancer cells were transfected with R97/R98, anti-miR-214 reduced miR-214 expression and impaired transendothelial migration were observed. Noteworthy, when the same cells were injected in the tail vein of mice, cell extravasation and metastatic nodule formation in lungs were strongly reduced. Thus, suggesting that R97/R98 anti-miR-214 oligonucleotides were able to inhibit tumor cell escaping through the endothelium. More importantly, when R97/R98 anti-miR-214 compounds were systemically delivered to mice carrying melanomas or breast or neuroendocrine pancreatic cancers, a reduced number of circulating tumor cells and lung or lymph node metastasis formation were detected. Similar results were also obtained when AAV8-miR-214 sponges were used in neuroendocrine pancreatic tumors. Based on this evidence, we propose miR-214 as a promising target for anti-metastatic therapies.

AB - We previously demonstrated that miR-214 is upregulated in malignant melanomas and triple-negative breast tumors and promotes metastatic dissemination by affecting a complex pathway including the anti-metastatic miR-148b. Importantly, tumor dissemination could be reduced by blocking miR-214 function or increasing miR-148b expression or by simultaneous interventions. Based on this evidence, with the intent to explore the role of miR-214 as a target for therapy, we evaluated the capability of new chemically modified anti-miR-214, R97/R98, to inhibit miR-214 coordinated metastatic traits. Relevantly, when melanoma or breast cancer cells were transfected with R97/R98, anti-miR-214 reduced miR-214 expression and impaired transendothelial migration were observed. Noteworthy, when the same cells were injected in the tail vein of mice, cell extravasation and metastatic nodule formation in lungs were strongly reduced. Thus, suggesting that R97/R98 anti-miR-214 oligonucleotides were able to inhibit tumor cell escaping through the endothelium. More importantly, when R97/R98 anti-miR-214 compounds were systemically delivered to mice carrying melanomas or breast or neuroendocrine pancreatic cancers, a reduced number of circulating tumor cells and lung or lymph node metastasis formation were detected. Similar results were also obtained when AAV8-miR-214 sponges were used in neuroendocrine pancreatic tumors. Based on this evidence, we propose miR-214 as a promising target for anti-metastatic therapies.

KW - anti-mir-214

KW - metastasis

KW - tumor progression

UR - http://www.scopus.com/inward/record.url?scp=85048774600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048774600&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2018.05.020

DO - 10.1016/j.ymthe.2018.05.020

M3 - Article

AN - SCOPUS:85048774600

VL - 26

SP - 2008

EP - 2018

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 8

ER -